Clinical Trial

Individualized Dynamic Frailty-tailored Therapy (DynaFiT) in Elderly Patients With NDMM

Study acronym: DynaFiT
Recruiting
View on ClinicalTrials.gov →
Summary
Frailty is dynamic and confers poor outcomes in elderly patients with newly diagnosed multiple myeloma (NDMM), mainly because of the high prevalence of treatment discontinuation due to intolerability. We designed a multi-center prospective study (DynaFiT) based on our real-life practice to evaluate the feasibility and benefits of a dynamic frailty-tailored therapy in elderly patients with different fitness/frailty statuses. Since Dara-based treatment have recently become the new standard regimens, in this amendment of the study, daratumumab added to VRd is recommended as induction therapy regimen.
Protocol Amendment History 8 amendments
This ClinicalTrials.gov record has been amended 8 times since 2023-10-19; most recent amendment 2026-02-11.
Status change: Not Yet Recruiting → Recruiting 2024-07-05
Trial Details
NCT Number NCT06099912
Lead Sponsor FengYan Jin
Collaborators: Sun Yat-Sen University Cancer Center, Ruijin Hospital, Second Hospital of Shanxi Medical University, The First Affiliated Hospital of Air Force Medicial University
Conditions Multiple Myeloma, Frailty
Enrollment 131 participants
Start Date 2021-09-08
Primary Completion 2026-09-08 (estimated)
Study Completion 2029-09-08 (estimated)
Updated on ClinicalTrials.gov 2026-02-12